Is Caris Life Sciences, Inc. Common Stock (CAI) overvalued? · rev $216.8M
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ.
This page asks whether Caris Life Sciences, Inc. Common Stock (CAI) looks expensive on cached numbers — not a short thesis.
Latest reported CAI revenue for 2025-09-30 was $216.8M. Net income was $24.3M. Revenue was up 19.5% from 2025-06-30 to 2025-09-30. CAI currently screens at market cap $5.22B.
CAI currently screens at market cap $5.22B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CAI 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CAI stock page for the full model, not this heading.
Not investment advice.